Evidence map›Paper›PMID 32855421›Full record

ArticleNature communications2020

Isobutanol production freed from biological limits using synthetic biochemistry.

Saken Sherkhanov, Tyler P Korman, Sum Chan, Salem Faham, Hongjiang Liu, Michael R Sawaya, Wan-Ting Hsu, Ellee Vikram, Tiffany Cheng, James U Bowie

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 86 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Activation-Free Upgrading of Carboxylic Acids to Aldehydes and Alcohols.bioRxiv : the preprint server for biology · 2025
    Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Polyhydroxyalkanoate Copolymer Production by RecombinantBioengineering (Basel, Switzerland) · 2024
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Saken SherkhanovDepartment of Chemistry and Biochemistry, Molecular Biology Institute, UCLA-DOE Institute, University of California, Los Angeles, CA, USA.
Tyler P KormanDepartment of Chemistry and Biochemistry, Molecular Biology Institute, UCLA-DOE Institute, University of California, Los Angeles, CA, USA.
Sum ChanDepartment of Chemistry and Biochemistry, Molecular Biology Institute, UCLA-DOE Institute, University of California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0003-3103-5954
Salem FahamVertex Pharmaceuticals, Boston, MA, USA.
Hongjiang LiuDepartment of Chemistry and Biochemistry, Molecular Biology Institute, UCLA-DOE Institute, University of California, Los Angeles, CA, USA.
Michael R SawayaDepartment of Chemistry and Biochemistry, Molecular Biology Institute, UCLA-DOE Institute, University of California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0003-0874-9043
Wan-Ting HsuDepartment of Chemistry and Biochemistry, Molecular Biology Institute, UCLA-DOE Institute, University of California, Los Angeles, CA, USA.
Ellee VikramDepartment of Chemistry and Biochemistry, Molecular Biology Institute, UCLA-DOE Institute, University of California, Los Angeles, CA, USA.
Tiffany ChengDepartment of Chemistry and Biochemistry, Molecular Biology Institute, UCLA-DOE Institute, University of California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0003-4588-1174
James U BowieDepartment of Chemistry and Biochemistry, Molecular Biology Institute, UCLA-DOE Institute, University of California, Los Angeles, CA, USA. bowie@mbi.ucla.edu.ORCID http://orcid.org/0000-0003-2249-5908
University of California, Los Angeles · USVertex Pharmaceuticals (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cost competitive conversion of biomass-derived sugars into biofuel will require high yields, high volumetric productivities and high titers. Suitable production parameters are hard to achieve in cell-based systems because of the need to maintain life processes. As a result, next-generation biofuel production in engineered microbes has yet to match the stringent cost targets set by petroleum fuels. Removing the constraints imposed by having to maintain cell viability might facilitate improved production metrics. Here, we report a cell-free system in a bioreactor with continuous product removal that produces isobutanol from glucose at a maximum productivity of 4 g L

Indexed as

Acetolactate SynthaseAdenosine TriphosphateAlcohol OxidoreductasesBiochemistryBioreactorsButanolsCell-Free SystemDirected Molecular EvolutionEnzymesEscherichia coli ProteinsGlucoseTemperatureThermodynamicsAcetolactate SynthaseAdenosine TriphosphateAlcohol OxidoreductasesButanolsEnzymesEscherichia coli ProteinsGlucoseisobutyl alcoholYahK protein, E coli

Identifiers

PMID32855421
PMCPMC7453195
OpenAlexW3080704512

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.